Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17972720 | 0.89 | LGALS1 (0.40) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL12387752 | 0.85 | CYP1A2 (0.41) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL20953682 | 0.84 | CYP1A2 (0.34) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL19057369 | 0.84 | LMNA (0.36) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL25089951 | 0.83 | SIGMAR1 (0.37) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL26147452 | 0.82 | LGALS1 (0.36) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL24941942 | 0.82 | LGALS1 (0.36) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL26700632 | 0.79 | LGALS1 (0.35) | LGALS1NPSR1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL13450956 | 0.79 | DNM1 (0.50) | LGALS1DNM1NPSR1ALDH1A1CYP1A2 | |
| SCHEMBL25063765 | 0.79 | EPHX2 (0.45) | ALDH1A1LMNATSHRPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020117974-A1 | COMPOUNDS AND COMPOSITIONS FOR EYE TREATMENTS | AVEDRO, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | LGALS1 4439/4885DNM1 3134/4885NPSR1 1062/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | LGALS1 4588/4885DNM1 2409/4885NPSR1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.